CEL-SCI Corporation Develops Immune-Based Treatment for Swine Flu and H1N1 Viruses

Strategic Insights -

CEL-SCI Corporation has announced the development of an immune-based treatment for the swine flu and related H1N1 viruses, utilizing its proprietary L.E.A.P.S.(TM) vaccine technology. The company aims to leverage its expertise in developing protective and therapeutic vaccines to create a therapeutic treatment for individuals infected with the swine and H1N1 flu viruses. This project has commenced pre-clinical testing, building on previous successes with the CEL-1000 peptide, which showed adjuvant activity when used with a peptide-based malaria vaccine and a DNA-based malaria vaccine in animal challenge studies.

Key Takeaways:

  • CEL-SCI Corporation is developing an immune-based treatment for swine flu and H1N1 viruses using its L.E.A.P.S.(TM) vaccine technology.
  • The company has commenced pre-clinical testing for the new treatment, leveraging its expertise in developing protective and therapeutic vaccines.
  • The L.E.A.P.S. technology has previously demonstrated adjuvant activity with a peptide-based malaria vaccine and a DNA-based malaria vaccine in animal challenge studies.
  • CEL-1000, a peptide derived from the L.E.A.P.S. technology, induced significant increases in protection in animals when used with the mentioned vaccines.
  • The L.E.A.P.S. technology has shown potential in addressing various diseases, including rheumatoid arthritis, malaria, tuberculosis, and herpes simplex viruses.
  • Adjuvants, like L.E.A.P.S., are designed to improve the effectiveness of vaccines by eliciting a more powerful immune response.
  • The L.E.A.P.S. technology may be used to overcome the virus' mutations by focusing on more conserved and common epitopes critical for viral function.

Statistics:

  • The L.E.A.P.S. technology has shown potential in addressing various diseases, as demonstrated by its effectiveness in inducing protection and/or improvement in diseases such as rheumatoid arthritis, malaria, TB, and herpes simplex viruses.
  • CEL-SCI has operations in Vienna, Virginia, and Baltimore, Maryland.
  • The company has developed products that empower immune defenses, including Multikine, which is being prepared for a global Phase III trial.

Sources:

  • CEL-SCI Corporation (NEWS: CEL-SCI Corporation - CEL-SCI Corporation Developing L.E.A.P.S. Based Immune System of Man (ISM) to Address High Resolution Infectious Diseases, Including Swine/H1N1 Flu and Related Emerging Diseases)
  • Vaccine Weekly editors (Copyright 2009, Vaccine Weekly via NewsRx.com)
  • Various medical and scientific reports from staff and other reports.